DIFFUSE large B-cell lymphomasTHERAPEUTICSLYMPHOMASIntroduction: Routine sick fund claims data provide a meaningful and reliable base for the in‐ and outpatient treatment landscape. Real world data (RWD) from Germany was used to describe treatment patterns for Diffuse Large B‐cell Lymphoma (DLBCL),...
摘要: Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive subtype of non-Hodgkin's lymphomas, with limited treatment options in refractory and relapsed patients. Growing evi... 查看全部>>关键词: CXCR5(+) CD8(+) T cell Diffuse large B-cell lymphoma Interleukin 10 ...
we performed a series of bioinformatic analyses. First, we delved into the linkage with a series of biological indicators via PheWAS. The identified genes were significantly related with a range of biochemistry (especially, cholesterol-related indexes), inflammatory (white blood cell and neutrophil), ...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
involving 10 disease classes under the FDR-correctedP < 0.05 (Supplementary Data13and Supplementary Fig.2a). For example,TET2(idiopathic thrombocytopenic purpura [ITP]-related gene) was associated with Hodgkin’s lymphoma, leukemia, pneumonia, and purpura. For common variants, we identified 1820...
In addition to individual variants, recent studies have evaluated genome-wide genetic correlations between pairs of cancer types4,5,6. One evaluated 13 cancer types and found shared heritability between kidney and testicular cancers, diffuse large B-cell lymphoma (DLBCL) and osteosarcoma, DLBCL and...
S2k-Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021 2022, JDDG - Journal of the German Society of Dermatology Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: An individual patient-level analysis of multiple randomiz...
Diffuse large B-cell lymphoma 210 1.04 (0.92–1.17) 1 1.40 (0.88–2.23) 1.48 (0.92–2.38) 1.63 (1.00–2.66) c 0.06 Follicular lymphoma 154 0.89 (0.75–1.05) 1 0.78 (0.48–1.26) 0.75 (0.46–1.25) 0.66 (0.37–1.16) 0.16 CLL/SLL 226 1.03 (0.91–1.16) 1 1.01 (0.68–1.52) 1.18 (0....
Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug, combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as...
(rs17749561). Our results align with those from Sampson et al.30, which showed an association between a PRS for CLL and the risk of diffuse large B-cell lymphoma, the most common NHL subtype. Both CLL and NHL arise from B-cells, and recent classifications account for their similar ...